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Because of the remarkable features, including biocompatibility and biodegradability, DNA origami
nanostructures have drawn much attention as ideal carriers for drug delivery. However, the cellular
uptake of DNA origami nanostructures was a passive targeting process, resulting in limited therapeutic
eﬀect. To address this problem, we anchored the aptamer C2NP (Apt) on rectangular DNA origami
nanostructures (RE) to enhance the tumor targeting properties and anticancer eﬀects of doxorubicin
(DOX). Apt was anchored onto RE with low or high density (RE-4Apt, RE-16Apt), followed by incubation
with DOX to obtain DOX@RE-4Apt and DOX@RE-16Apt. The results showed that DOX@RE-4Apt and
DOX@RE-16Apt exhibited excellent biocompatibility and targeting ability, as well as a synergic biological
eﬀect with chemotherapy on cancer therapy. More importantly, after conjugation with RE, the bioactivity
of Apt was signiﬁcantly increased. These results revealed that Apt anchored DNA nanostructures not only
are potential carriers for precise therapy, but also supply a strategy to enhance the bioactivity of aptamers.1. Introduction
Recently, DNA origami nanostructures have witnessed a rapid
development since the concept was rst proposed by Seeman.1
With a versatile and “one-pot” method, Rothemund made
another contribution to DNA nanotechnology. In his work,
diﬀerent two-dimensional shapes of DNA nanostructures, such
as rectangles and pentagrams, have been constructed through
rational design.2 The scaﬀold DNA (long single stranded DNA)
can be easily folded into a nanoscale by hundreds of staples
(short single stranded DNA). This simple single-step method
makes fantastic nanomaterials via DNA origami.
Up to now, proteins, peptides, and nanoparticles have been
site-specically anchored on DNA origami based on non-
covalent or covalent bonds, demonstrating that DNA origami
nanostructures exhibit a powerful role in microarrays.3–7,22
Furthermore, DNA nanostructures as a type of biomaterial show
natural properties, including superb stability, excellentu University, Zhengzhou, Henan 450001,
ax: +86 0371 67739546; Tel: +86 0371
Diagnosis for Critical Diseases, Henan
hina
rlsruhe Institute of Technology, 76344
al Technology, Ministry of Education of
na
tion (ESI) available. See DOI:
e work.
08biocompatibility, and biodegradability. These remarkable
features have made the DNA nanostructure an ideal carrier for
cell culture study and in vivo study.8 For example, Liedl's group
used DNA origami nanostructures as carriers for CpG oligonu-
cleotides to study immunostimulation in mammalian cells.9 In
Mikkila's study, DNA origami nanostructures were coated with
virus capsid proteins by electrostatic interaction for enhancing
intracellular delivery.10 Church's group designed a hollow DNA
nanorobot with a smart gate keeper system to deliver antibodies
for tissue culture.11
Instead of such complex nanorobots, DNA base-pairs based
simple nanostructures are seen as alternative carriers for
doxorubicin (DOX) since DOX could insert into the DNA double
helix by hydrogen bonds between the amino group of DOX and
the cytosine of DNA.12–14 Recently, several groups have used DNA
origami nanostructures to deliver DOX for anticancer
therapy.15–17 However, since they lack ligands, DNA origami
nanostructures showed a passive tumor targeting process, the
result of which was that little DOX was eﬀectively delivered to
the therapeutic target sites. To address this problem, a possible
solution is to modify DNA nanostructures with some ligands
which can specically recognize cancer cell markers.18
C2NP (Apt), a novel DNA aptamer, was selected by systematic
evolution of ligands by exponential enrichment (SELEX) and
exhibited high aﬃnity to the CD30 cell marker.19 Apt has been
utilized as a probe for tumor imaging, with high sensitivity and
a long-lasting signal.20 Aer binding to CD30 receptors, the
downstream signalling will be activated, inducing the apoptosis
of T-cell lymphoma cells.21 Based on the fact that Apt is a DNA
aptamer with 31 nucleotides in length, Apt could easily beThis journal is © The Royal Society of Chemistry 2018
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View Article Onlineconjugated to DNA origami nanostructures by hybridization
method or designing a staple strand which contains the Apt
sequence.23 However, up to now, little attention has been paid
on Apt modied DNA origami nanostructures for targeting
delivery and gene therapy.
In our present work, Apt mediated tumor targeted and gene
therapy systems were developed. Apt was anchored onto DNA
origami nanostructures with diﬀerent densities and the anti-
cancer drug DOX was loaded for chemotherapy. A human
anaplastic large cell lymphoma cell line (K299) which over-
express CD30 receptors, was chosen for the targeting study.
Additionally, the mechanism and bioactivity of Apt and Apt-RE
were explored. Our results showed that the DNA nanocarriers
constructed in this work exhibited chemotherapy of DOX and
biotherapy of Apt concurrently. The bioactivity of Apt was
signicantly increased aer conjugation to DNA
nanostructures.
2. Materials and methods
2.1. Materials
M13mp18 was purchased from New England Biolabs. K299 cells
(a human anaplastic large cell lymphoma cell line) were ob-
tained from CoBioer (Nanjing, China). Single stranded DNA was
synthesized by BIONEER (Daejeon, Korea). Agarose was
supplied by Biowest (Nuaille´, France). Fetal bovine serum (FBS)
was purchased from BI (Kibbutz, Israel). All other agents and
chemicals were obtained from Solarbio (Beijing, China). All
these commercial chemicals and agents were used without any
modication.
2.2. Preparation of DNA origami nanostructures
Rectangular DNA origami nanostructures (RE) were assembled
following Rothmund's method. Briey, scaﬀold strands
(M13mp18) and stable strands were mixed in water at a molar
ratio of 1 : 10 in a PCR tube. Then folding buﬀer (nal
concentration: Tris base 10 mM, EDTA 5 mM, magnesium
acetate 12.5 mM) was introduced into the system. Folding was
carried out by cooling the system down from 95 C to 20 C
slowly (0.016 C s1) and maintaining at 20 C for another 20 s
in a PCR Thermocycler (SENSO, Germany). To prepare 4 or 16
Apt conjugated DNA origami nanostructures (RE-4Apt and RE-
16Apt), the pre-targeting DNA origami nanostructures were
rstly synthesized. Basically, stable strands in the designated
sites were replaced with capture single stranded DNA (Fig. S1†).
Aer follow the same procedure, the pre-targeting DNA origami
nanostructures was obtained, followed by incubation with Apt
overnight at room temperature. Biotin labelled Apt was used to
obtain RE-4Apt@Biotin and RE-16Apt@Biotin for atomic force
microscopy (AFM) analysis.
2.3. Characterization of DNA nanostructures
RE, RE-4Apt, and RE-16Apt were characterized by agarose (1%,
m V1) gel electrophoresis at 100 V for 60 min in an ice bath. In
the preparation of the agarose gel, 2 mL of ethidium bromide (10
mg mL1) was added for gel imaging (BIORAD, USA). FurtherThis journal is © The Royal Society of Chemistry 2018characterization was carried out by AFM (Bruck, Germany). RE-
4Apt@Biotin and RE-16Apt@Biotin were rst puried by
Microcon® Centrifugal lters (Merck, Germany), and the puri-
ed RE-4Apt@Biotin and RE-16Apt@Biotin were introduced
onto two micas. Aer 5 min, streptavidin was dropped and
incubated with RE-4Apt@Biotin and RE-16Apt@Biotin for
several minutes, respectively.21 The micas were washed with 1
TAE buﬀer several times, followed by observation with AFM
under liquid model.2.4. Drug loading
Doxorubicin (DOX) was loaded into DNA origami nano-
structures by incubating DOX$HCl solution with DNA origami
nanostructures in the dark at room temperature.14 To obtain the
maximum DOX-loading, the amount of DOX initially added and
the incubation time were optimized, respectively. In brief,
various amounts of DOX (20 mL; 2000, 1000, 500, 100, 50, 25, 10,
5 mM) were incubated with DNA origami nanostructures (20 mL;
3.3 nM) for 6 h. Then the mixtures were centrifuged down at
12000 rpm for 10 min, followed by quantication using
a microplate reader (BioTek, USA; lex ¼ 485 nm, lem ¼ 591 nm).
The incubation time was also varied from 1 h to 36 h to obtain
the maximum DOX loading, and the loading capacity was
measured by the same method.
The drug-loading capacity of DOX@RE was calculated by the
diﬀerential measurement of the supernatant concentration,
and the equation is as follow:
DOX loading capacity ð%Þ
¼ nDOXadded  nDOXsupernatant
nDOXadded
 100%2.5. Stability evaluation
The stability of both RE and DOX were evaluated by incubating
DOX@RE with cell culture medium in the dark at 37 C.
Samples were collected at diﬀerent time points (1, 5, 8, 12, 24,
48, 72 h) and analyzed by agarose gel electrophoresis to study
the stability of RE. The relative uorescence intensity was
determined using microplate reader at set time points (0, 0.5, 1,
3, 8, 15, 24, 48, 72 h).2.6. Drug release
Slide-A-Lyzer™ MINI Dialysis Devices (Thermo Fisher, Ger-
many) were used to study the release of DOX fromDOX@RE and
DOX@RE-Apt in PBS (pH 5.0 and 7.4) at 37 C. Firstly, DOX@RE
and DOX@RE-Apt were separately suspended in folding buﬀer.
Then suspensions (20 mL) of each were added to a dialysis
device. At set time points (0.5, 1, 2, 4, 8, 12, 24, 48 h), three
dialysis tubes of each sample were taken out and the DOX
remaining inside the tube was quantied. The cumulative
release was calculated by the following equation:RSC Adv., 2018, 8, 26300–26308 | 26301
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View Article OnlineCumulative release ð%Þ
¼ DOXtotal DOXremaining inside the tube
DOXtotal
 100%2.7. Cell culture
K299 cells were cultivated with RPMI Medium 1640 containing
5% FBS under standard conditions (37 C, 5% CO2). Only cells
in the exponential phase were used for the following
experiments.2.8. In vitro anticancer activity
Cytotoxicity of free DOX, DOX@RE, DOX@RE-4Apt and
DOX@RE-16Apt were tested against the K299 cell line by
a standard CCK8 assay. Typically, K229 cells were seeded in 96
well plates (1104 cells per well) and cultured under standard
cell culture conditions. Aer 12 h, DOX, DOX@RE, DOX@RE-
4Apt, or DOX@RE-16Apt (DOX nal concentration: 10, 5, 1,
0.5, 0.1 mM; n ¼ 5) was added and further cultivated for 24, 48,
or 72 h, respectively. At the end of the experiment, CCK8 was
added following the manufacturer's instructions for the cell
counting kit. Cell culture medium was used as a blank control
and cells cultivated with normal cell culture medium were
applied as a positive group. The inhibition rate was calculated
by the following equation:
Cell inhibition rate ð%Þ
¼ ðODcontrol ODblankÞ 

ODdrug ODblank

ðODcontrol ODblankÞ  100%2.9. In vitro bioactivity of Apt
To evaluate the bioactivity of Apt, various amounts of free Apt,
RE-4Apt, and RE-16Apt (Apt nal concentration: 16, 32, 64, 128
nM) were incubated with K299 cells for 72 h. The inhibition rate
was determined by the same method. With respect to chemo-
therapy and biotherapy of drug loaded systems, diﬀerent
concentrations of DOX@RE, DOX@RE-4Apt, and DOX@RE-
16Apt were treated with K299 for 48 h, using free DOX as
a positive control. Proliferation was analyzed by CCK8.2.10. Confocal laser scanning microscopy (CLSM)
5  105 of K299 cells per well were seeded in 24-well plates
overnight before being treated with DOX, DOX@RE, DOX@RE-
4Apt, and DOX@RE-16Apt (nal concentration: RE: 4 nM, DOX:
2 mM). Aer incubation for 2 h, the uptake process was stopped
by the addition of cold PBS to the plate. The cells were further
washed 3 times with PBS to remove the redundant DOX or drug
loaded systems. Subsequently, the cells were xed with 4%
paraformaldehyde. Aer a wash with PBS, the cells were sus-
pended in PBS and observed by CLSM (Nikon A1, Japan).26302 | RSC Adv., 2018, 8, 26300–263082.11. Cellular uptake
The cells were seeded in 24-well plates at a density of 5  105
cells per well and incubated overnight at standard cell culture
conditions. DOX, DOX@RE, DOX@RE-4Apt, and DOX@RE-
16Apt (nal concentration: RE: 4 nM, DOX: 2 mM) were
added and incubated for 2 h. Then, cellular uptake was
stopped by introducing 1 mL of cold PBS to each well. The cells
were washed with PBS for 3 times prior to ow cytometric
analysis (BD FACSCanto II, USA).2.12. Cell apoptosis and cell cycle
Cell apoptosis was evaluated by a double staining technology
with an annexin V-FITC and propidium iodide (PI) kit. Typi-
cally, cells (2  105 cells per mL, 2 mL per well) were seeded in
24-well plates and incubated at standard cell culture condi-
tions overnight. 1 mL of upper cell culture medium was care-
fully removed and replaced by 1 mL of fresh cell culture
medium containing DOX, DOX@RE, DOX@RE-4Apt,
DOX@RE-16Apt, Apt, RE, RE-4Apt, or RE-16Apt (nal concen-
tration: RE: 4 nM, DOX: 2 mM). The cells were collected and
washed thrice with PBS aer incubation for 24 h. Aer that,
the cells were suspended in 100 mL of binding buﬀer followed
by treatment with FITC-Annexin V (5 mL, 5 min) and PI (5 mL,
10 min) in turn. Another 200 mL of binding buﬀer was added to
dilute the cell mixtures before ow cytometric analysis.
With respect to cell cycle analysis, cells were collected and
xed with 70% of ethanol at 4 C overnight. Following the
washing step (PBS 3), the cells were treated with 100 mL of
Rnase A at 37 C for 30 min. Then, 200 mL of PI solution was
introduced to stain the cells for another 30 min. The cells were
analyzed by ow cytometry.2.13. Reactive oxygen species (ROS)
ROS in tumor cells were analyzed by a reactive oxygen species
assay kit. Briey, cells were seeded in a 24-well plate and treated
with DOX, DOX@RE, DOX@RE-4Apt, DOX@RE-16Apt, Apt, RE,
RE-4Apt, or RE-16Apt (nal concentration: RE: 4 nM, DOX: 2
mM). Aer incubation for 24 h, the cells were collected and
washed 3 times with PBS. Subsequently, the cells were sus-
pended in 500 mL of cell culture medium (without FBS) con-
taining DCFH-DA at a concentration of 10 mM. For the positive
control group, an additional 10 mL of Rosup was added. The
cells were incubated under standard conditions for 25 min and
washed several times with cell culture medium (without FBS)
and PBS before ow cytometric analysis.2.14. Statistical analysis
All data was expressed as the mean  SD. The results of ow
cytometric analysis were performed by Flow Jo soware. All
experiments in this study were conducted at least in triplicate.This journal is © The Royal Society of Chemistry 2018
Scheme 1 Schematic illustration of targeting DNA origami nanostructures for biotherapy and chemotherapy. Aptamer C2NP were anchored on
the top of DNA nanostructures with diﬀerent densities (RE-4Apt, RE-16Apt). On one hand, aptamer C2NP can help DOX loaded DNA origami
nanostructures (DOX@RE-4Apt, DOX@RE-16Apt) get into cells eﬀectively, enhancing the anticancer activity of DOX. On the other hand, C2NP
can induce cell apoptosis, exhibiting synergic biological eﬀect with chemotherapy on cancer therapy.
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View Article Online3. Results and discussion
3.1. Construction and characterization of DNA origami
nanostructures
Aptamer C2NP anchored DNA origami nanostructures were
designed and constructed in this work (Scheme 1). The list of
DNA sequences used in this paper are shown in Table S1.†With
the help of staples, M13mp18 was folded into a rectangle shape
by Rothmund's method.2 The edged staples were removed to
avoid coupling between the DNA origami nanostructures which
was caused by the U–U accumulation eﬀect of the DNA bases.19
The diﬀerent densities of Apt were precisely anchored onto the
top of the DNA origami nanostructures by the hybridization
method with V-shaped structures (RE-4Apt, RE-16Apt).20 On one
hand, Apt anchored RE could help DOX loaded carriers get intoFig. 1 Characterization of DNA origami nanostructures. (A) Gel electroph
single M13mp18; (3) RE; (4) RE-4Apt; 5.RE-16Apt). (B) AFM image of RE-
This journal is © The Royal Society of Chemistry 2018cells eﬀectively, enhancing the anticancer activity of DOX. On
the other hand, because Apt could induce cell apoptosis, DOX
loaded and Apt anchored RE can exhibit synergic biological
eﬀects with chemotherapy on anticancer therapy.
The correct folding of DNA origami nanostructures was
characterized by agarose gel electrophoresis and AFM. As shown
in Fig. 1A, lane 3 shows a bright band between 6000 bp and 8000
bp which was tted to the designated size of RE. Electrophoretic
mobility of RE-4Apt was similar with RE, but much faster than
RE-16Apt, indicating the successful conjugation of Apt.
The high aﬃnity of biotin–streptavidin coupling was used to
make the aptamer conjugated DNA origami nanostructures be
easily observed by AFM. Fig. 1B and C exhibit details about the
morphology of the DNA origami nanostructures (size: 90 nm 
60 nm). Because of their exible properties, the aptamer couldoretic analysis of DNA origami nanostructures ((1) 1 kbp plus marker; (2)
4Apt. (C) AFM image of RE-16Apt.
RSC Adv., 2018, 8, 26300–26308 | 26303
Fig. 2 (A) Gel electrophoretic analysis of DOX-loaded DNA origami Nanostructures after incubation with cell culture medium at diﬀerent time
((1) 1 kb plus marker; (2) 1 h; (3) 5 h; (4) 8 h; (5) 12 h; (6) 24 h; (7) 48 h; (8) 72 h; (9) contrast). (B) The relative stability of DOX in cell culture medium.
(C) The release properties of DOX from DOX@RE or DOX@RE-Apt at pH 5.0 or 7.4.
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View Article Onlinebe wrapped into RE or pushed onto the other side of RE, making
a less conjugated aptamer visible. Insuﬃcient interactions
between biotin and streptavidin was another reason for the
fewer numbers.3.2. Drug loading, stability and release
DOX could be intercalated into the DNA duplex with the help of
hydrogen bonds between the amino group of DOX and the
cytosine of DNA.13 Based on this feature, DNA nanostructures
could be used as carriers to deliver DOX to living cells in vitro or
in vivo. With respect to RE, DOX was loaded into RE by incu-
bating them in the dark at room temperature. Maximum drug
loading was obtained when 50 mM of DOX was incubated with
3.3 nM of RE (one DOX molecule per base pair).
With respect to drug eﬃcacy, the ability to release the drugs
from their carriers is an important property. Drug burst release,
usually caused by the structural damage of carriers, would
shorten the half-life of drugs and show local or systemic
toxicity.21,24 To avoid DOX burst release caused by damage to the
DNA origami nanostructure, the stability of DOX@RE was
evaluated in cell culture medium before further study. As shown
in Fig. 2A, DOX@RE maintained its structure at least 72 h inFig. 3 In vitro K299 cell inhibition analysis of free DOX, DOX@RE, DOX@R
26304 | RSC Adv., 2018, 8, 26300–26308a cell culture medium containing 5% FBS. At the same time, the
relative stability of DOX was signicantly increased (Fig. 2B).
DOX could easily diﬀuse into the surrounding environment
which exhibited a lesser DOX concentration.17 Compared with
free DOX, DOX release from DOX@RE or DOX@RE-Apt showed
a controlled and slower release property at diﬀerent pH values.
The release properties of DOX from RE or RE-Apt showed no
diﬀerences at pH 7.0, while much more DOX defused into the
surroundings at pH 5.5 than at pH 7.4 at the same time point
(Fig. 2C), exhibiting that the acid conditions slightly accelerate
the release of DOX. This is probably because acid might accel-
erate the degradation of the DNA origami nanostructures or
weaken the hydrogen bonds between DOX and the DNA strands.
These results showed that DNA origami based DOX delivery
system was valuable for further anticancer study.3.3. In vitro anticancer activity
In vitro anticancer activity of DOX@RE, DOX@RE-4Apt, and
DOX@RE-16Apt were evaluated on K299 cells. To determine the
cytotoxicity of the buﬀer and DNA materials, the folding buﬀer
and RE were incubated with K299 cells, respectively. According
to Table S2,† both folding buﬀer and RE had no signicantE-4Apt and DOX@RE-16Apt against at (A) 24 h, (B) 48 h, (C) 72 h (n¼ 5).
This journal is © The Royal Society of Chemistry 2018
Fig. 4 (A) Bioactivity of Apt, RE-4Apt, and RE-16Apt at diﬀerent concentration on K299 cells. Synergetic bioactivity and chemotherapy of
DOX@RE-4Apt and DOX@RE-16Apt which loaded with diﬀerent amount of DOX on K299 cells with the ﬁnal concentration of Apt 16 nM (B),
32 nM (C), 64 nM (D). (n ¼ 5) (note: free DOX at diﬀerent concentration was used as positive control).
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View Article Onlineeﬀects on the cell inhibition rate at the concentration used in
the following studies.
Fig. 3 shows the cell inhibition rates of DOX, DOX@RE,
DOX@RE-4Apt, and DOX@RE-16Apt. Each group showed
a greater inhibition rate with a greater DOX concentration and
longer incubation time. As shown in Fig. 2B, the relativeFig. 5 (A) CLSM images of K299 cells after incubation with free DOX, DO
histograms of intracellular DOX uptake after incubation with free DOX, D
This journal is © The Royal Society of Chemistry 2018stability of DOX was increased aer being loaded into DNA
origami nanostructure. DOX loaded into RE, RE-4Apt, and RE-
16Apt revealed much greater cytotoxicity than free DOX at the
same concentration and at the same incubation time.
Compared with DOX@RE, DOX@RE-4Apt and DOX@RE-16Apt
exhibited much stronger anticancer eﬀects in vitro.X@RE, DOX@RE-4Apt, and DOX@RE-16Apt for 2 h. (B) Flow cytometry
OX@RE, DOX@RE-4Apt and DOX@RE-16Apt for 2 h.
RSC Adv., 2018, 8, 26300–26308 | 26305
Fig. 6 The impacts of free DOX and diﬀerent DNA origami carriers on cell apoptosis (A) cell cycle (B) and RSO content (C) after incubation for
24 h.
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View Article OnlineFurthermore, the inhibition rate of DOX@RE-16Apt was much
greater than DOX@RE-4Apt.
The results demonstrated that aptamer conjugated RE
enhanced the anticancer activity of DOX. The anticancer activity
was further increased when additional Apt was modied onto
DNA origami nanostructure. This is probably because26306 | RSC Adv., 2018, 8, 26300–26308DOX@RE-16Apt recognized cells easily, and was taken up
eﬀectively by activating more receptors simultaneously.25
Apt was selected by SELEX as a ligand to CD30. The activated
CD30 would regulate the downstream signal pathway, resulting
in cancer cell apoptosis. It was also reported that aer incuba-
tion with serum at 37 C for 24 h, Apt still maintained its abilityThis journal is © The Royal Society of Chemistry 2018
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View Article Onlineto bind CD30.19 However, biotherapy of aptamer usually
occurred aer 72 h of treatment with cells at a high concen-
tration.26 To evaluate if DNA origami carriers eﬀected the
bioactivity of Apt, K299 cells were treated with diﬀerent
concentrations of Apt, RE-4Apt, RE-16Apt. The results in Fig. 4A
show that the bioactivities of Apt were enhanced with
increasing concentration. At the same concentration, RE-4Apt
and RE-16Apt resulted in an increase of inhibition rate, indi-
cating that RE-4Apt and RE-16Apt enhanced the anticancer
activity of Apt. The possible reason was that the stability of
aptamer was increased in these two carriers.27 At the same
concentration, more Apt maintain their activity in RE-4Apt and
RE-16Apt groups. Compared with RE-4Apt and RE-16Apt,
DOX@RE-4Apt and DOX@RE-16Apt further increased the
inhibition rate, indicating that these carriers achieved chemo-
therapy and biotherapy simultaneously (Fig. 4B–D).3.4. Cellular uptake
CLSM was performed to explore the cellular uptake of
DOX@RE, DOX@RE-4Apt and DOX@RE-16Apt. As shown in
Fig. 5A, the DOX signal in cells was detected aer incubation
with DOX@RE, DOX@RE-4Apt, and DOX@RE-16Apt for 4 h,
indicating that DOX was successfully delivered into cells.
Compared with the free DOX group, the DOX@RE group
showed a brighter red uorescence, probably due to the
increased stability of DOX loaded into the RE carriers. In other
words, at the same concentration of DOX, much more DOX
could be eﬀectively delivered into cells in the DOX@RE group.
Besides, the signal of DOX was much stronger in the DOX@RE-
4Apt group and the strongest in the DOX@RE-16Apt group.
With the help of Apt, more DOX@RE-4Apt and DOX@RE-16Apt
entered into cells by CD30 mediated endocytosis,28 especially in
DOX@RE-16Apt which contained a high density of Apt. These
results were further proved by ow cytometric analysis (Fig. 5B).
The DOX level in the DOX@RE-16Apt group was the greatest
(56.84%) while still much greater in the DOX@RE-4Apt
(30.23%) and the DOX@RE (26.84%) groups, demonstrating
that Apt promoted the cellular uptake of DOX, and that a high
density of Apt exhibited an advantage in this process.3.5. Mechanism of cell inhibition
It is generally known that the anticancer activity of DOX is
achieved by inhibiting topoisomerase II and resulting in DNA
damage.29 Previous research has shown that DOX eﬀected cell
apoptosis, cell cycle and the intracellular ROS level. With
respect to Apt, publications indicated that Apt activated CD30,
resulting in cell apoptosis. However, more details are still
unclear. In this paper, cell apoptosis, cell cycle, and ROS were
analysed to understand the possible cell inhibition mechanism
of Apt and whether the nanocarriers constructed in this study
could enhance the activity of DOX or not. According to Fig. 6A,
Apt, RE-4Apt and RE-16Apt enhanced early apoptosis. With the
help of DOX, cell apoptosis was signicantly increased in the
DOX@RE, DOX@RE-4Apt and DOX@RE-16Apt group. Cell cycle
results (Fig. 6B) showed that Apt increased cell arrest in the G2This journal is © The Royal Society of Chemistry 2018phase slightly while DOX loaded RE systems enhanced the G2
phase arrest signicantly.
ROS play an important role in both normal bioactivities and
abnormal pathological processes. On one hand, increased ROS
stress could enhance cell proliferation. On the other hand, high
levels of ROS would cause DNA damage and result in cell
apoptosis.30 As shown in Fig. 6C, the intracellular level of ROS
was increased aer treatment with DOX, which agreed with the
report that DOX could induce ROS generation in cancer cells.31
Interestingly, Apt also showed the ability to cause great levels of
ROS, while RE alone had no signicant inuence on ROS.
Compared with Apt, the RE-4Apt and RE-16Apt groups exhibited
merits in increasing intracellular ROS. ROS was further upre-
gulated in the DOX@RE, DOX@RE-4Apt and DOX@RE-16Apt
groups. Fig. 6 indicates that Apt exhibited anticancer activity
by enhancing early apoptosis and upregulating ROS levels. With
the help of anticancer drug, DOX, cell apoptosis, cell cycle arrest
and ROS were enhanced, revealing that DNA nanocarriers
constructed in this study were more eﬃcacious because of the
synergistic eﬀect of DOX and Apt.4. Conclusion
For the rst time aptamer C2NP was modied onto DNA
origami nanostructures for a targeting drug delivery system. Apt
enhanced the anticancer activity of DOX loaded DNA origami
delivery systems, especially in the high density and closely
positioned system (DOX@RE-16Apt). Besides, high concentra-
tions of Apt induced additional cell apoptosis, cycle arrest in the
G2 phase and high levels of ROS. Aer conjugation with DNA
nanostructures, the bioactivity of Apt was signicantly
increased. What's more, DNA nanocarriers constructed in this
work exhibited chemotherapy of DOX and biotherapy of Apt
simultaneously. This work conrms that the DNA nano-
structure is a promising carrier, not only for drugs, but also for
aptamers. The controllable site immobilization of ligands and
high drug loading capacity make DNA origami nanostructures
a powerful carrier for drug delivery and a novel approach for the
precise treatment against tumors. Apt anchored DNA nano-
structures also supply a strategy to enhance the bioactivity of
Apt itself.Conﬂicts of interest
The authors declare that there is no conict of interest.Acknowledgements
This work was nancially supported by the National Natural
Science Foundation of China (NSFC No. 81573011 and
81611130076).References
1 N. C. Seeman, J. Theor. Biol., 1982, 99, 237–247.
2 P. W. K. Rothemund, Nature, 2006, 440, 297–302.RSC Adv., 2018, 8, 26300–26308 | 26307
RSC Advances Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
3 
Ju
ly
 2
01
8.
 D
ow
nl
oa
de
d 
on
 9
/4
/2
01
8 
12
:3
2:
39
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online3 N. V. Voigt, T. Torring, A. Rotaru, M. F. Jacobsen,
J. B. Ravnsbaek, R. Subramani, W. Mamdouh, J. Kjems,
A. Mokhir, F. Besenbacher and K. V. Gothelf, Nat.
Nanotechnol., 2010, 5, 200–203.
4 R. Chhabra, J. Sharma, Y. Ke, Y. Liu, S. Rinker, S. Lindsay and
H. Yan, J. Am. Chem. Soc., 2007, 129, 10304–10305.
5 B. A. Williams, K. Lund, Y. Liu, H. Yan and J. C. Chaput,
Angew. Chem., Int. Ed. Engl., 2007, 46, 3051–3054.
6 B. Ding, Z. Deng, H. Yan, S. Cabrini, R. N. Zuckermann and
J. Bokor, J. Am. Chem. Soc., 2010, 132, 3248–3249.
7 Y. Zhang, J. Chao, H. Liu, F. Wang, S. Su, B. Liu, L. Zhang,
J. Shi, L. Wang, W. Huang, L. Wang and C. Fan, Angew.
Chem., Int. Ed. Engl., 2016, 55, 8036–8040.
8 J. Chao, H. Liu, S. Su, L. Wang, W. Huang and C. Fan, Small,
2014, 10, 4626–4635.
9 V. J. Schuller, S. Heidegger, N. Sandholzer, P. C. Nickels,
N. A. Suhartha, S. Endres, C. Bourquin and T. Liedl, ACS
Nano, 2011, 5, 9696–9702.
10 J. Mikkila, A. P. Eskelinen, E. H. Niemela, V. Linko,
M. J. Frilander, P. Torma and M. A. Kostiainen, Nano Lett.,
2014, 14, 2196–2200.
11 S. M. Douglas, I. Bachelet and G. M. Church, Science, 2012,
335, 831–834.
12 V. Bagalkot, O. C. Farokhzad, R. Langer and S. Jon, Angew.
Chem., Int. Ed., 2006, 45, 8149–8152.
13 D. Agudelo, P. Bourassa, G. Berube and H. A. Tajmir-Riahi,
Int. J. Biol. Macromol., 2014, 66, 144–150.
14 P. C. Sun, N. Zhang, Y. F. Tang, Y. N. Yang, X. Chu and
Y. X. Zhao, Int. J. Nanomed., 2017, 12, 2657–2672.
15 Q. Jiang, C. Song, J. Nangreave, X. W. Liu, L. Lin, D. L. Qiu,
Z. G. Wang, G. Z. Zou, X. J. Liang, H. Yan and B. Q. Ding,
J. Am. Chem. Soc., 2012, 134, 13396–13403.
16 Q. Zhang, Q. Jiang, N. Li, L. R. Dai, Q. Liu, L. L. Song,
J. Y. Wang, Y. Q. Li, J. Tian, B. Q. Ding and Y. Du, ACS
Nano, 2014, 8, 6633–6643.26308 | RSC Adv., 2018, 8, 26300–2630817 Y. X. Zhao, A. Shaw, X. H. Zeng, E. Benson, A. M. Nystrom
and B. Hogberg, ACS Nano, 2012, 6, 8684–8691.
18 J. Li, H. Pei, B. Zhu, L. Liang, M. Wei, Y. He, N. Chen, D. Li,
Q. Huang and C. Fan, ACS Nano, 2011, 5, 8783–8789.
19 P. Parekh, S. Kamble, N. X. Zhao, B. P. Portier and Y. L. Zu,
Biomaterials, 2013, 34, 8909–8917.
20 Z. H. Zeng, P. Parekh, Z. Li, Z. Z. Shi, C. H. Tung and Y. L. Zu,
Theranostics, 2014, 4, 945–952.
21 V. J. O'Sullivan, I. Barrette-Ng, E. Hommema,
G. T. Hermanson, M. Schoeld, S. C. Wu,
C. Honetschlaeger, K. K. S. Ng and S. L. Wong, PLoS One,
2012, 7, e35203.
22 J. Yang, Z. C. Song, S. Liu, Q. Zhang and C. Zhang, ACS Appl.
Mater. Interfaces, 2016, 8, 22451–22456.
23 Y. Ke, S. Lindsay, Y. Chang, Y. Liu and H. Yan, Science, 2008,
319, 180–183.
24 X. Huang and C. S. Brazel, J. Controlled Release, 2001, 73,
121–136.
25 A. Angelin, S. Weigel, R. Garrecht, R. Meyer, J. Bauer,
R. K. Kumar, M. Hirtz and C. M. Niemeyer, Angew. Chem.,
Int. Ed., 2015, 54, 15813–15817.
26 H. Kaur, J. J. Li, B. H. Bay and L. Y. L. Yung, PLoS One, 2013,
8, 11.
27 P. Charoenphol and H. Bermudez, Mol. Pharm., 2014, 11,
1721–1725.
28 M. K. Kennedy, C. R. Willis and R. J. Armitage, Immunology,
2006, 118, 143–152.
29 G. Capranico, F. Zunino, K. W. Kohn and Y. Pommier,
Biochemistry, 1990, 29, 562–569.
30 H. Pelicano, D. Carney and P. Huang, Drug Resist. Updates,
2004, 7, 97–110.
31 S. W. Wang, E. A. Konorev, S. Kotamraju, J. Joseph,
S. Kalivendi and B. Kalyanaraman, J. Biol. Chem., 2004,
279, 25535–25543.This journal is © The Royal Society of Chemistry 2018
